miR-193a levels in leukemia and cell lines. Relative qRT-PCR quantification of miR-193a level in mononucleated cells (MNC) isolated from 42 leukemia patients (A) and 81 AML FAB M2 subtype patients (B). Cases were grouped into 2 categories: those with (AML1/ETO⁺) and without (AML1/ETO⁻) t(8;21). AML1/ETO⁻ cases had higher miR-193a expression levels (P = .0005). (C) Serial analyses of miR-193a levels in samples isolated from 4 individual leukemia patients with disease progression. (D) Relative quantification of miR-193a levels in the indicated leukemia cell lines (*P = .0007). (E) Relative quantification of miR-193a levels in HL-60, Kasumi-1, SKNO-1 (WT, mock, and siA/E). The results represent the average of 3 independent evaluations ± SD (*P = .001). (F) Top panel: Relative quantification of miR-193a levels in U937 (Mock and A/E-HA) cells. The results represent the average of 3 independent evaluations ± SD (*P = .006). Bottom panels: Immunoblot analysis for AML1 and AML1/ETO with an anti-AML1 antibody. β-actin was used for protein loading control. Zn²⁺ treatment (100μM for 16 hours) was used to increase the expression of AML1/ETO in U937 cells.